Lenalidomide Plus Rituximab in the Community: Strengths, Limitations, and the Right Patient Profile

In 'Lenalidomide Plus Rituximab in the Community: Strengths, Limitations, and the Right Patient Profile,' Tara Graff, DO, MS delves into the following critical questions:

Lenalidomide plus rituximab is one option in second-line therapy. Which patients are the best candidates for this regimen?

What are the strengths and limitations of this regimen?

Tara Graff examined the evolution of R² in community oncology practice, reflecting on how the combination represented a genuine game changer when it emerged in the second-line follicular lymphoma setting approximately, offering patients a chemo-free option with meaningful improvements in PFS and time to next therapy that distinguished it from simply retreating patients with rituximab monotherapy. She also discussed the real-world dynamics of community uptake, noting that despite compelling efficacy data, adoption lagged initially as community oncologists questioned the added value of lenalidomide. This hesitation was gradually overcome as the synergistic mechanism of the combination became better understood, and as the fact that most community oncologists were already experienced with lenalidomide from its use in multiple myeloma reduced the learning curve around side effect management. Tara Graff further highlighted that the strengths of R² in the community setting lie not only in its clinical efficacy but also in its practical accessibility while acknowledging that the addition of lenalidomide does introduce its own side effect burden that must be weighed thoughtfully against the benefit for each individual patient.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Tafasitamab Plus R² in the Community: Familiarity, Adoption, and the Shift Toward Personalized Second-Line Care,' features Tara Graff advancing her conversation on follicular lymphoma and focusing on how community oncologists' existing familiarity with both tafasitamab from the diffuse large B-cell lymphoma setting and the R² backbone positions them well to adopt this triplet regimen, and how the widening landscape of second-line options is bringing personalized medicine principles to the forefront of RRFL treatment decision-making in community practice.